| Identification | Back Directory | [Name]
BMS 303141 | [CAS]
943962-47-8 | [Synonyms]
CS-887
BMS30314
BMS 303141
BMS 303141, >=98%
BMS303141; BMS 303141
BMS-303141 >=98% (HPLC)
3,5-dichloro-2-hydroxy-N-(4-Methoxybiphenyl-3-yl)benzenesulfonaMide
3,5-dichloro-2-hydroxy-N-(2-methoxy-5-phenylphenyl)benzenesulfonamide
3,5-Dichloro-2-hydroxy-N-(4-methoxy[1,1'-biphenyl]-3-yl)benzenesulfonamide
Benzenesulfonamide, 3,5-dichloro-2-hydroxy-N-(4-methoxy[1,1'-biphenyl]-3-yl)-
3,5-Dichloro-2-hydroxy-N-(4-methoxy[1,1'-biphenyl]-3-yl)-benzenesulfonamide BMS 303141 | [Molecular Formula]
C19H15Cl2NO4S | [MDL Number]
MFCD25976797 | [MOL File]
943962-47-8.mol | [Molecular Weight]
424.3 |
| Chemical Properties | Back Directory | [Boiling point ]
591.5±60.0 °C(Predicted) | [density ]
1.462±0.06 g/cm3(Predicted) | [storage temp. ]
2-8°C | [solubility ]
DMSO: soluble20mg/mL, clear | [form ]
powder | [pka]
4.94±0.48(Predicted) | [color ]
white to beige | [Stability:]
Stable for 2 years from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 3 months. |
| Hazard Information | Back Directory | [Description]
BMS-303141 (943963-47-8) is a potent and selective ATP citrate lyase (ACL) inhibitor, IC50=0.13 μM. Inhibits lipid biosynthesis, IC50=8 μM in HepG2 cells.1,2?Reduces weight gain, lowers plasma cholesterol, triglycerides and glucose in high-fat-fed mice.2?A novel tool compound for exploring the potential of ACL inhibition as a target for metabolic disorders such as obesity and dyslipidemia.2?Impairs proliferation or induces death in androgen-depleted castration resistant prostate cancer cells.3?Reduces cell cycle progression in iBN cells.4 | [Uses]
BMS-303141 has been used for inhibition of ATP citrate lyase in breast cancer cell lines. | [Definition]
ChEBI: 3,5-dichloro-2-hydroxy-N-(2-methoxy-5-phenylphenyl)benzenesulfonamide is a member of biphenyls. | [Biochem/physiol Actions]
BMS-303141 is a potent inhibitor of ATP citrate lyase (ACL). BMS-303141 inhibits lipid synthesis in HepG2 cells with an IC50 of 8 μM, and lowers plasma triglycerides in a murine hyperlipdemia model. | [storage]
Store at -20°C | [References]
1) Li?et al. (2007),?2-hydroxy-N-arylbenzenesulfonamides as ATP-citrate lyase inhibitors; Bioorg. Med. Chem.,?17?3208
2) Ma?et al.?(2009),?A novel direct homogeneous assay for ATP citrate lyase; J. Lipid Res.,?50?2131
3) Shah?et al.?(2016),?Targeting ACLY sensitizes castration-resistant prostate cancer cells to AR antagonism by impinging on an ACLY-AMPK-AR feedback mechanism; Oncotarget,?7?43713
4) Rhee and Dekoter (2017),?Regulation of Lipid Metabolism and Cell Cycle Progression by PU.1 in Myeloid Progenitor Cells; Blood,?130?2433 |
|
|